Showing results (171-180 of 302) with videos related to
Sort By:
Pageof 31
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 3, 2021
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaJustin Ferdinandus, Wolfgang P Fendler, Katharina Lueckerath, et al.Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.Cancer Treatment Reviews|February 29, 2016
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapyThomas K Eigentler, Jessica C Hassel, Carola Berking, et al.International Journal of Cancer|January 20, 2017
IRF4 rs12203592 functional variant and melanoma survivalMiriam Potrony, Aida Rebollo-Morell, Pol Giménez-Xavier, et al.BMC Cancer|October 25, 2019
Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case reportAnn-Kathrin Stoppek, Sied Kebir, Andreas Junker, et al.Medicine|November 19, 2016
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapyKatharina C Kaehler, Christine Blome, Andrea Forschner, et al.Cancer Treatment Reviews|May 28, 2017
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactionsJessica C Hassel, Lucie Heinzerling, Jens Aberle, et al.Pigment Cell & Melanoma Research|August 1, 2022
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsAnne Zaremba, Friedegund Meier, Christian Schlein, et al.Theranostics|January 7, 2020
Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo18F-FDG-PETJohannes Schwenck, Barbara Schörg, Francesco Fiz, et al.Oncotarget|April 6, 2017
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIoana Cosgarea, Selma Ugurel, Antje Sucker, et al.Pageof 31